Catalog
- Results include
-
Sutanfōdo Daigaku kyōju ga oshieru jukusui no shūkan
Nishino, SeijiDaiichihan. 第一版. - Kōtō-ku [Tokyo] : Kabushiki Kaisha PHP Kenkyūjo, 2019. 江東区 [Tokyo] : 株式会社 PHP 研究所, 2019. -
Sutanfodo-shiki saiko no suimin = The Stanford Method for Ultimate Sound Sleep
Nishino, Seiji, 1955-Shohan. 初版. - Tōkyō : Sanmāku Shuppan, 2017. 東京 : サンマーク出版, 2017. -
The orexin/hypocretin system : physiology and pathophysiology
Totowa, N.J. : Humana Press, ©2005.This cutting-edge review of the orexin/hypocretin system sets the stage for advanced research on the pathological mechanisms underlying the loss of orexin/hypocretin neurons in humans, regulation of sleep and wakefulness by the orexin/hypocretin system, and the role of the orexin/hypocretin system in many other physiological processes, including feeding, autonomic regulation, and neuroendocrine regulation. Topics of interest include assessment of functions and the physiology of orexin/hypocretin, its pathophysiology in human narcolepsy-cataplexy, and possible treatments and pharmacology. The a.Orexin/hypocretin research began in 1998, as a result of the discovery of a new hypothalamic neuropeptide. In 1999, it was found that mutations in the orexin/ hypocretin-related genes caused a sleep disorder (narcolepsy) in dogs and mice. These findings were soon followed by the discoveries of orexin/hypocretin ligand deficiency in human narcolepsy. The finding of the major pathophysiological mechanisms of human narcolepsy resulted in its reclassification as a neurological, not a psychiatric, disorder. The - portance of early diagnosis and initiation of treatment for human narcolepsy has been repeatedly emphasized because the disease typically starts around puberty (when social and school influences become important). Orexin/hypocretin de- ciency in narcolepsy subjects can be detected clinically in cerebrospinal fluid (CSF) orexin/hypocretin measures (low CSF orexin/hypocretin levels are strongly asso- ated with narcolepsy-cataplexy among various neurologic and sleep disorders). Thus, the CSF orexin/hypocretin measurements are expected to be included as a diagnostic test for narcolepsy-cataplexy in the second revision of international di- nostic criteria (ICSD). This positive diagnostic test is very useful for establishing an early diagnosis for narcolepsy-cataplexy, and many patients will likely receive im- diate benefits. Cerebrospinal orexin/hypocretin measurements are also informative for the nosological classification of hypersomnia. Because orexin/hypocretin de- ciency is observed in most human narcolepsy-cataplexy, orexin/hypocretin repla- ment therapy is now a promising new choice for the treatment of human narcolepsy, and research in this area is actively in progress.
Online SpringerLink
Guides
Library website
Exhibits
EarthWorks
More search tools
Tools to help you discover resources at Stanford and beyond.